These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 29923053

  • 21. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.
    Gleize V, Alentorn A, Connen de Kérillis L, Labussière M, Nadaradjane AA, Mundwiller E, Ottolenghi C, Mangesius S, Rahimian A, Ducray F, POLA network, Mokhtari K, Villa C, Sanson M.
    Ann Neurol; 2015 Sep; 78(3):355-74. PubMed ID: 26017892
    [Abstract] [Full Text] [Related]

  • 22. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM, Alvi MA, Bydon M, Quinones-Hinojosa A, Chaichana KL.
    Clin Neurol Neurosurg; 2019 Jul; 182():32-36. PubMed ID: 31063969
    [Abstract] [Full Text] [Related]

  • 23. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
    Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski CM, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Chen W, Iafrate AJ, Chi AS, Zagzag D, Golfinos JG, Placantonakis DG, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M.
    Neuro Oncol; 2019 Sep 06; 21(9):1164-1174. PubMed ID: 31140557
    [Abstract] [Full Text] [Related]

  • 24. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG, Jiang H, Lim-Fat MJ, Sahebjam S, Kiehl TR, Karamchandani J, Coire C, Chung C, Millar BA, Laperriere N, Mason WP.
    Can J Neurol Sci; 2017 May 06; 44(3):288-294. PubMed ID: 28488951
    [Abstract] [Full Text] [Related]

  • 25. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis.
    Zhang ZY, Chan AK, Ng HK, Ding XJ, Li YX, Shi ZF, Zhu W, Zhong P, Wang Y, Mao Y, Yao Y, Zhou LF.
    Int J Clin Exp Pathol; 2014 May 06; 7(12):8627-36. PubMed ID: 25674227
    [Abstract] [Full Text] [Related]

  • 26. Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.
    Li G, Huang R, Fan W, Wang D, Wu F, Zeng F, Yu M, Zhai Y, Chang Y, Pan C, Jiang T, Yan W, Wang H, Zhang W.
    Front Immunol; 2021 May 06; 12():800928. PubMed ID: 34956239
    [Abstract] [Full Text] [Related]

  • 27. Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis?
    Gozé C, Rigau V, Gibert L, Maudelonde T, Duffau H.
    J Neurooncol; 2009 Jan 06; 91(1):1-5. PubMed ID: 18726074
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.
    Neurol Med Chir (Tokyo); 2007 Aug 06; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [Abstract] [Full Text] [Related]

  • 29. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.
    Neuro Oncol; 2017 Jun 01; 19(6):786-795. PubMed ID: 28340142
    [Abstract] [Full Text] [Related]

  • 30. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
    Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA.
    Oncologist; 2019 May 01; 24(5):664-670. PubMed ID: 30777895
    [Abstract] [Full Text] [Related]

  • 31. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
    Kim JW, Park CK, Park SH, Kim YH, Han JH, Kim CY, Sohn CH, Chang KH, Jung HW.
    J Neurol Neurosurg Psychiatry; 2011 Feb 01; 82(2):224-7. PubMed ID: 20587495
    [Abstract] [Full Text] [Related]

  • 32. Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm.
    van der Voort SR, Incekara F, Wijnenga MMJ, Kapas G, Gardeniers M, Schouten JW, Starmans MPA, Nandoe Tewarie R, Lycklama GJ, French PJ, Dubbink HJ, van den Bent MJ, Vincent AJPE, Niessen WJ, Klein S, Smits M.
    Clin Cancer Res; 2019 Dec 15; 25(24):7455-7462. PubMed ID: 31548344
    [Abstract] [Full Text] [Related]

  • 33. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
    Darlix A, Deverdun J, Menjot de Champfleur N, Castan F, Zouaoui S, Rigau V, Fabbro M, Yordanova Y, Le Bars E, Bauchet L, Gozé C, Duffau H.
    J Neurooncol; 2017 May 15; 133(1):37-45. PubMed ID: 28434111
    [Abstract] [Full Text] [Related]

  • 34. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
    Aliotta E, Batchala PP, Schiff D, Lopes BM, Druzgal JT, Mukherjee S, Patel SH.
    J Neurooncol; 2019 Nov 15; 145(2):257-263. PubMed ID: 31531788
    [Abstract] [Full Text] [Related]

  • 35. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
    Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.
    Neuro Oncol; 2012 Sep 15; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
    [Abstract] [Full Text] [Related]

  • 36. [The clinical relevance of 1p19q codeletion of oligodendrogliomas at the Department of Neurosurgery in Debrecen].
    Klekner A, Fekete G, Rencsi M, Méhes G, Szabó P, Bognár L.
    Ideggyogy Sz; 2012 Jan 30; 65(1-2):17-24. PubMed ID: 22338842
    [Abstract] [Full Text] [Related]

  • 37. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C, Alentorn A, Idbaih A, Simó M, Kaloshi G, Ricard D, Barritault M, Meyronet D, Bruna J, Honnorat J, Delattre JY, Ducray F.
    J Neurooncol; 2018 Feb 30; 136(3):533-539. PubMed ID: 29143276
    [Abstract] [Full Text] [Related]

  • 38. Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors.
    Kitahama K, Iijima S, Sumiishi A, Hayashi A, Nagahama K, Saito K, Sasaki N, Kobayashi K, Shimizu S, Nagane M, Shibahara J.
    Brain Tumor Pathol; 2021 Jan 30; 38(1):23-29. PubMed ID: 32989606
    [Abstract] [Full Text] [Related]

  • 39. alpha-Internexin expression identifies 1p19q codeleted gliomas.
    Ducray F, Crinière E, Idbaih A, Mokhtari K, Marie Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M.
    Neurology; 2009 Jan 13; 72(2):156-61. PubMed ID: 19139367
    [Abstract] [Full Text] [Related]

  • 40. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
    Khurana R, Rath S, Singh HB, Rastogi M, Nanda SS, Chauhan A, Kaif M, Hussain N.
    Asian Pac J Cancer Prev; 2020 Mar 01; 21(3):755-760. PubMed ID: 32212804
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.